Cephalochromin Effects in Triple-Negative Breast Cancer Cells: Apoptosis Induction and Modulation of Survival...

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) lacks targeted therapies due to absent hormone and HER2 receptors.
• Survivin (BIRC5) overexpression in TNBC promotes tumor growth, chemoresistance, and poor outcomes.
• Cephalochromin, a fungal compound, has shown anti-cancer activity but its effects on breast cancer are unknown.

Purpose of the Study:

• To evaluate the antineoplastic potential of cephalochromin in breast cancer cells.
• To investigate its effects on cell viability, apoptosis, cell cycle, and survivin expression.
• To explore its mechanistic actions and synergistic effects with standard chemotherapies.

Main Methods:

• Cell viability assays, apoptosis assays, cell cycle analysis.
• Western blotting for apoptosis markers (PARP1), DNA damage (γH2AX), and autophagy (SQSTM1/p62, LC3BII).
• Gene expression analysis and drug combination studies with paclitaxel and doxorubicin.

Main Results:

• Cephalochromin demonstrated potent cytotoxicity in TNBC cells, inducing apoptosis and cell cycle arrest.
• It downregulated survivin expression and modulated key regulators of apoptosis, DNA damage, and autophagy.
• Cephalochromin enhanced the efficacy of paclitaxel and doxorubicin, exhibiting synergistic interactions.

Conclusions:

• Cephalochromin possesses significant antineoplastic activity against triple-negative breast cancer.
• It targets multiple pathways including apoptosis, DNA damage response, and autophagy, while downregulating survivin.
• Cephalochromin shows promise as a therapeutic agent for TNBC, potentially improving treatment outcomes and warranting further investigation.